Top

Published in:

Open Access 01-12-2014 | Original research

Feasibility of preoperative ¹²⁵I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer

Authors: Bas Pouw, Linda J de Wit-van der Veen, Daan Hellingman, Oscar R Brouwer, Marie-Jeanne TFD Vrancken Peeters, Marcel PM Stokkel, Renato A Valdés Olmos

Published in: EJNMMI Research | Issue 1/2014

Abstract

Background

This study was designed to explore the feasibility of replacing the conventional peri-/intratumoural ultrasound (US)-guided technetium-99m albumin nanocolloid (^99mTc-nanocolloid) administration by an injection of the same tracer guided by a freehand single-photon emission computed tomography (SPECT) device in patients with non-palpable breast cancer with an iodine-125 (¹²⁵I) seed as tumour marker, who are scheduled for a sentinel lymph node biopsy (SLNB). This approach aimed to decrease the workload of the radiology department, avoiding a second US-guided procedure.

Methods

In ten patients, the implanted ¹²⁵I seed was primarily localised using freehand SPECT and subsequently verified by conventional US in order to inject the ^99mTc-nanocolloid. The following 34 patients were injected using only freehand SPECT localisation. In these patients, additional SPECT/CT was acquired to measure the distance between the ^99mTc-nanocolloid injection depot and the ¹²⁵I seed. In retrospect, a group of 21 patients with US-guided ^99mTc-nanocolloid administrations was included as a control group.

Results

The depth difference measured by US and freehand SPECT in ten patients was 1.6 ± 1.6 mm. In the following 36 ¹²⁵I seeds (34 patients), the average difference between the ¹²⁵I seed and the centre of the ^99mTc-nanocolloid injection depot was 10.9 ± 6.8 mm. In the retrospective study, the average distance between the ¹²⁵I seed and the centre of the ^99mTc-nanocolloid injection depot as measured in SPECT/CT was 9.7 ± 6.5 mm and was not significantly different compared to the freehand SPECT-guided group (two-sample Student's t test, p = 0.52).

Conclusion

We conclude that using freehand SPECT for ^99mTc-nanocolloid administration in patients with non-palpable breast cancer with previously implanted ¹²⁵I seed is feasible. This technique may improve daily clinical logistics, reducing the workload of the radiology department.

Available only for authorised users

Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012, 367: 1998–2005. 10.1056/NEJMoa1206809CrossRefPubMed

Liebregts ME, van Riet YE, Nieuwenhuijzen GP, Rutten HJT, Duijm LEM, Voogd AC: Patterns and determinants of surgical management of screen detected breast cancer in the South-East Netherlands. Breast 2013, 22: 713–717. 10.1016/j.breast.2012.12.003CrossRefPubMed

Sajid MS, Parampalli U, Haider Z, Bonomi R: Comparison of radioguided occult lesion localization (ROLL) and wire localization for non-palpable breast cancers: a meta-analysis. J Surg Oncol 2012, 105: 852–858. 10.1002/jso.23016CrossRefPubMed

Postma EL, Witkamp AJ, van den Bosch MA, Verkooijen HM, van Hillegersberg R: Localization of nonpalpable breast lesions. Expert Rev Anticancer Ther 2011, 11: 1295–1302. 10.1586/era.11.116CrossRefPubMed

Fusco R, Petrillo A, Catalano O, Sansone M, Granata V, Filice S, D'Aiuto M, Pankhurst Q, Douek M:Procedures for location of non-palpable breast lesions: a systematic review for the radiologist. Breast Cancer. 2012. [10.1007/s12282–012–0427–1]

Kuijt GP, van de Poll-Franse LV, Voogd C, Nieuwenhuijzen GP, Roumen RMH: Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 2007, 33: 832–837. 10.1016/j.ejso.2006.11.017CrossRefPubMed

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HMC, Wolmark N: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11: 927–933. 10.1016/S1470-2045(10)70207-2PubMedCentralCrossRefPubMed

Tanis PJ, Deurloo EE, Valdés Olmos RA, Rutgers EJ, Nieweg OE, Besnard APE, Kroon BBR: Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001, 8: 850–855. 10.1007/s10434-001-0850-6CrossRefPubMed

Van Esser S, Hobbelink MGG, Peeters PHM, Buskens E, van der Ploeg IM, Mali WPTHM, Borel Rinkes IHM, Hillegersberg R: The efficacy of ‘radio guided occult lesion localization’ (ROLL) versus ‘wire-guided localization’ (WGL) in breast conserving surgery for non-palpable breast cancer: a randomized clinical trial - ROLL study. BMC Surg 2008, 8: 9. 10.1186/1471-2482-8-9PubMedCentralCrossRefPubMed

10.

Jakub JW, Gray RJ, Degnim AC, Boughey JC, Gardner M, Cox CE: Current status of radioactive seed for localization of non palpable breast lesions. Am J Surg 2010, 199: 522–528. 10.1016/j.amjsurg.2009.05.019CrossRefPubMed

11.

Donker M, Drukker CA, Valdés Olmos RA, Rutgers EJT, Loo CE, Sonke GS, Wesseling J, Alderliesten T, Vrancken Peeters MJTFD: Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. Ann Surg Oncol 2013, 20: 2569–2575. 10.1245/s10434-013-2921-xCrossRefPubMed

12.

Wang Z, Wu L-C, Chen J-Q: Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat 2011, 129: 675–689. 10.1007/s10549-011-1665-1CrossRefPubMed

13.

Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S: Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999, 229: 860–864. discussion 864–5 10.1097/00000658-199906000-00013PubMedCentralCrossRefPubMed

14.

Chagpar A, Martin RC, Chao C, Wong SL, Edwards MJ, Tuttle T, McMasters KM: Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 2004, 139: 614–618. discussion 618–620 10.1001/archsurg.139.6.614CrossRefPubMed

15.

Lin KM, Patel TH, Ray A, Ota M, Jacobs L, Kuvshinoff B, Chung M, Watson M, Ota DM: Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg 2004, 199: 561–656. 10.1016/j.jamcollsurg.2004.06.018CrossRefPubMed

16.

Brouwer OR, Vermeeren L, van der Ploeg IMC, Valdés Olmos RA, Loo CE, Pereira-Bouda LM, Smit F, Neijenhuis P, Vrouenraets BC, Sivro-Prndelj F, Jap-a-Joe SM, Borgstein PJ, Rutgers EJ, Oldenburg HSA: Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern? Results of a Dutch multicentre study (MULTISENT). Eur J Nucl Med Mol Imaging 2012, 39: 1137–1143. 10.1007/s00259-012-2131-yCrossRefPubMed

17.

Pesek S, Ashikaga T, Krag LE, Krag D: The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg 2012, 36: 2239–2251. 10.1007/s00268-012-1623-zPubMedCentralCrossRefPubMed

18.

Estourgie SH, Nieweg OE, Olmos RAV, Rutgers EJT, Kroon BBR: Lymphatic drainage patterns from the breast. Ann Surg 2004, 239: 232–237. 10.1097/01.sla.0000109156.26378.90PubMedCentralCrossRefPubMed

19.

Gobardhan PD, Madsen EVE, van Dalen T, Perre CI, Bongers V: Ultrasound-guided sentinel node procedure for nonpalpable breast carcinoma. Nucl Med Commun 2012, 33: 80–83. 10.1097/MNM.0b013e32834cd71fCrossRefPubMed

20.

Rieger A, Saeckl J, Belloni B, Hein R, Okur A, Scheidhauer K, Wendler T, Traub J, Friess H, Martignoni ME: First experiences with navigated radio-guided surgery using freehand SPECT. Case Rep Oncol 2011, 4: 420–425. 10.1159/000330273PubMedCentralCrossRefPubMed

21.

Valdés Olmos RA, Vidal-Sicart S, Nieweg OE: Technological innovation in the sentinel node procedure: towards 3-D intraoperative imaging. Eur J Nucl Med Mol Imaging 2010, 37: 1449–1451. 10.1007/s00259-010-1468-3CrossRefPubMed

22.

Brouwer OR, Buckle T, Bunschoten A, Kuil J, Vahrmeijer AL, Wendler T, Valdés-Olmos RA, van der Poel HG, van Leeuwen FW: Image navigation as a means to expand the boundaries of fluorescence-guided surgery. Phys Med Biol 2012, 57: 3123–3136. 10.1088/0031-9155/57/10/3123CrossRefPubMed

23.

Bland JM, Altman DG: Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995, 346: 1085–1087. 10.1016/S0140-6736(95)91748-9CrossRefPubMed

24.

Hamilton C, Stamey J: Using Bland-Altman to assess agreement between two medical devices–don't forget the confidence intervals! J Clin Monit Comput 2007, 21: 331–333. 10.1007/s10877-007-9092-xCrossRefPubMed

25.

Traub J, Wendler T: [http://www.surgiceye.com/en/declipseSPECT/openSurgery.html] http://www.surgiceye.com/en/declipseSPECT/openSurgery.html, 05–2014]. SurgicEye. GmbH.

26.

Chen W, Chen L, Yang S, Chen Z, Qian G, Zhang S, Jing J: A novel technique for localization of small pulmonary nodules. Chest 2007, 131: 1526–1531. 10.1378/chest.06-1017CrossRefPubMed

Title: Feasibility of preoperative 125I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer
Authors: Bas Pouw
Linda J de Wit-van der Veen
Daan Hellingman
Oscar R Brouwer
Marie-Jeanne TFD Vrancken Peeters
Marcel PM Stokkel
Renato A Valdés Olmos
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2014
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-014-0019-5

ACC 2024 Congress

Springer Medicine

Feasibility of preoperative ¹²⁵I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with 177Lu-octreotate

11C-acetate PET/CT in pre-therapeutic lymph node staging in high-risk prostate cancer patients and its influence on disease management - a retrospective study

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer

Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model

Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount